212 related articles for article (PubMed ID: 8595169)
1. Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro.
Sen S; Erba E; D'Incalci M; Bottero F; Canevari S; Tomassetti A
Br J Cancer; 1996 Feb; 73(4):525-30. PubMed ID: 8595169
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.
Erba E; Sen S; Sessa C; Vikhanskaya FL; D'Incalci M
Br J Cancer; 1994 Feb; 69(2):205-11. PubMed ID: 8297715
[TBL] [Abstract][Full Text] [Related]
3. Role of membrane-associated folate binding protein in the cytotoxicity of antifolates in KB, IGROV1, and L1210A cells.
Schultz RM; Andis SL; Shackelford KA; Gates SB; Ratnam M; Mendelsohn LG; Shih C; Grindey GB
Oncol Res; 1995; 7(2):97-102. PubMed ID: 7579732
[TBL] [Abstract][Full Text] [Related]
4. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo.
Bottero F; Tomassetti A; Canevari S; Miotti S; Ménard S; Colnaghi MI
Cancer Res; 1993 Dec; 53(23):5791-6. PubMed ID: 8242637
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines.
Miotti S; Bagnoli M; Ottone F; Tomassetti A; Colnaghi MI; Canevari S
J Cell Biochem; 1997 Jun; 65(4):479-91. PubMed ID: 9178098
[TBL] [Abstract][Full Text] [Related]
6. Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate.
Pinard MF; Jolivet J; Ratnam M; Kathmann I; Molthoff C; Westerhof R; Schornagel JH; Jansen G
Cancer Chemother Pharmacol; 1996; 38(3):281-8. PubMed ID: 8646804
[TBL] [Abstract][Full Text] [Related]
7. Altered transport of folic acid and antifolates through the carrier mediated reduced folate transport system in a human leukemia cell line resistant to (6R) 5,10-dideazatetrahydrofolic acid (DDATHF).
Pavlovic M; Leffert JJ; Russello O; Bunni MA; Beardsley GP; Priest DG; Pizzorno G
Adv Exp Med Biol; 1993; 338():775-8. PubMed ID: 8304227
[No Abstract] [Full Text] [Related]
8. Growth of ovarian-carcinoma cell lines at physiological folate concentration: effect on folate-binding protein expression in vitro and in vivo.
Miotti S; Facheris P; Tomassetti A; Bottero F; Bottini C; Ottone F; Colnaghi MI; Bunni MA; Priest DG; Canevari S
Int J Cancer; 1995 Nov; 63(3):395-401. PubMed ID: 7591238
[TBL] [Abstract][Full Text] [Related]
9. 5,10-Dideazatetrahydrofolic acid (DDATHF) transport in CCRF-CEM and MA104 cell lines.
Pizzorno G; Cashmore AR; Moroson BA; Cross AD; Smith AK; Marling-Cason M; Kamen BA; Beardsley GP
J Biol Chem; 1993 Jan; 268(2):1017-23. PubMed ID: 8419310
[TBL] [Abstract][Full Text] [Related]
10. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier.
Zhao R; Gao F; Babani S; Goldman ID
Clin Cancer Res; 2000 Aug; 6(8):3304-11. PubMed ID: 10955817
[TBL] [Abstract][Full Text] [Related]
12. The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs.
Theti DS; Jackman AL
Clin Cancer Res; 2004 Feb; 10(3):1080-9. PubMed ID: 14871988
[TBL] [Abstract][Full Text] [Related]
13. Growth-inhibitory effects of 5,10-dideazatetrahydrofolic acid on variant murine L1210 and human CCRF-CEM leukemia cells with different membrane-transport characteristics for (anti)folate compounds.
Jansen G; Westerhof GR; Kathmann I; Rijksen G; Schornagel JH
Cancer Chemother Pharmacol; 1991; 28(2):115-7. PubMed ID: 2060081
[TBL] [Abstract][Full Text] [Related]
14. Role of folate receptor and reduced folate carrier in the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells.
Corona G; Giannini F; Fabris M; Toffoli G; Boiocchi M
Int J Cancer; 1998 Jan; 75(1):125-33. PubMed ID: 9426700
[TBL] [Abstract][Full Text] [Related]
15. Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines.
Ottone F; Miotti S; Bottini C; Bagnoli M; Perego P; Colnaghi MI; Ménard S
Br J Cancer; 1997; 76(1):77-82. PubMed ID: 9218736
[TBL] [Abstract][Full Text] [Related]
16. Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase.
Sanghani SP; Moran RG
Biochemistry; 1997 Aug; 36(34):10506-16. PubMed ID: 9265631
[TBL] [Abstract][Full Text] [Related]
17. Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor.
Theti DS; Bavetsias V; Skelton LA; Titley J; Gibbs D; Jansen G; Jackman AL
Cancer Res; 2003 Jul; 63(13):3612-8. PubMed ID: 12839949
[TBL] [Abstract][Full Text] [Related]
18. Effect of folate-binding protein on intestinal transport of folic acid and 5-methyltetrahydrofolate across Caco-2 cells.
Verwei M; van den Berg H; Havenaar R; Groten JP
Eur J Nutr; 2005 Jun; 44(4):242-9. PubMed ID: 15316828
[TBL] [Abstract][Full Text] [Related]
19. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
[TBL] [Abstract][Full Text] [Related]
20. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
